Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

Fig. 3

Safety evaluation of rmhTNF combined with cisplatin versus cisplatin alone through thoracic perfusion for treating MPE. a Combination of rmhTNF and cisplatin displays a higher incidence rate of fever than cisplatin alone. b Combination of rmhTNF and cisplatin has a similar incidence of chest pain with cisplatin alone. rmhTNF, recombinant mutant human tumor necrosis factor injection; MPE, malignant pleural effusion; OR, odds ratio

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us